SOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

SOD Sciences and Vivos Therapeutics (VVOS) announced a strategic partnership. Vivos acquired an 11% stake in SOD and 50% ownership of its pseudohypoxia patent and test for $12M in convertible preferred stock. The companies will jointly market the ReBalU Protocol to Vivos's customers, targeting 500,000 chronic disease patients. SOD retains other patents and protocol rights.

Original reporting
Published Oct 29, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VVOS
Bullish
high confidence
Mentioned
$VVOS
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$VVOSBullishMed
01

Why it matters

The deal creates a 50/50 ownership of a pseudohypoxia patent and test, potentially expanding Vivos' product suite and revenue.

02

Market read

First‑report of a $12M strategic investment that could affect Vivos' share price and the broader health‑tech sector.

03

What to watch

Regulatory clearance for the ReBalU test and reimbursement pathways remain uncertain.

Relevance 6/10Novelty 7/10Timing: immediate today

Background

Press release announcing a strategic partnership and equity investment between Vivos Therapeutics and SOD Sciences.

Company-level read

Ticker impact

$VVOSBullishHigh confidence
Context

Vivos Therapeutics acquired an 11% equity stake in SOD Sciences and received $12M of convertible preferred stock in a new strategic partnership.

Expected impact

likely upward pressure as investors price in the new revenue stream and cross‑selling opportunity.

Evidence & confidence

Equity investment and joint commercialization typically boost the investor's share price, especially with a sizable $12M cash infusion.

Market effects

May spur interest in other sleep‑apnea and chronic‑disease diagnostics firms.

U.S. health‑tech sector could see modest uplift.

Limited to U.S. biotech and health‑tech investors.

Counterpoint

The partnership could dilute SOD's focus and Vivos may overpay for a niche test with uncertain adoption.

Key entities

  • Vivos Therapeutics, Inc.

    Nasdaq‑listed sleep‑apnea treatment company acquiring stake in SOD Sciences.

  • SOD Sciences, Inc.

    Developer of the ReBalU Primed Cell Test and related patents.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.